Pfizer Expects 2024 Sales Of $61B-$64B Compared To Prior Guidance Of $59.5B-$62.5B And Consensus Of $61.156B
Portfolio Pulse from Benzinga Newsdesk
Pfizer has updated its 2024 sales guidance to a range of $61 billion to $64 billion, which is an increase from its previous guidance of $59.5 billion to $62.5 billion. This new guidance is also above the consensus estimate of $61.156 billion.
October 29, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has increased its 2024 sales guidance to $61B-$64B, higher than both its previous guidance and the consensus estimate. This suggests a positive outlook for the company's future performance.
Pfizer's updated sales guidance for 2024 is higher than both its previous guidance and the consensus estimate, indicating a stronger than expected performance outlook. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100